Skip to main content
Fig. 6 | European Journal of Medical Research

Fig. 6

From: CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer

Fig. 6

CDK6 had a higher expression in clinical PCa samples, PCa and EnzR PCa cells. A The mRNA expression of CDK6 in PCa tissues and para-cancerous normal tissues of 14 paired patients from Tongji Hospital. B The protein level of CDK6 between clinical PCa samples and para-cancerous normal tissues from 6 paired patients. C, D The mRNA and protein expression of CDK6 among normal prostate epithelial cell RWPE-1 and PCa cell lines LNCaP, and C4-2. E, F The mRNA and protein level of CDK6 between LNCaP cells not treated Enz and EnzR LNCaP cells. G, H The mRNA and protein expression of CDK6 between normal C4-2 cells and EnzR C4-2 cells. *represents P < 0.05, **represents P < 0.01. The data were shown in mean ± SD. The qRT-PCR and western blot using β-tubulin as inner control. N represents normal tissues and T represents tumor tissues. Parental means cells sensitive to Enz; EnzR means cells resistant to Enz

Back to article page